Mostrar el registro sencillo del ítem
dc.contributor.author | Elangovan, Ramyiadarsini | |
dc.contributor.author | Jenks, Michael | |
dc.contributor.author | Yun, Jason | |
dc.contributor.author | Dickson-Tetteh, Leslie | |
dc.contributor.author | Kirtley, Shona | |
dc.contributor.author | Hemelaar, Joris | |
dc.contributor.author | WHO-UNAIDS Network for HIV Isolation and Characterisation | |
dc.contributor.author | Delgado, Elena | |
dc.date.accessioned | 2022-09-19T08:24:50Z | |
dc.date.available | 2022-09-19T08:24:50Z | |
dc.date.issued | 2021-07-15 | |
dc.identifier.citation | Front Microbiol. 2021 Jul 15;12:690647. | es_ES |
dc.identifier.issn | 1664-302X | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/14992 | |
dc.description.abstract | Global HIV-1 genetic diversity forms a major obstacle to the development of an HIV vaccine. It may be necessary to employ subtype-specific HIV-1 vaccines in individual countries according to their HIV-1 subtype distribution. We estimated the global and regional need for subtype-specific HIV-1 vaccines. We took into account the proportions of different HIV-1 variants circulating in each country, the genetic composition of HIV-1 recombinants, and the different genome segments (gag, pol, env) that may be incorporated into vaccines. We modeled different scenarios according to whether countries would employ subtype-specific HIV-1 vaccines against (1) the most common subtype; (2) subtypes contributing more than 5% of HIV infections; or (3) all circulating subtypes. For therapeutic vaccines targeting the most common HIV-1 subtype in each country, 16.5 million doses of subtype C vaccine were estimated globally, followed by subtypes A (14.3 million) and B (4.2 million). A vaccine based on env required 2.6 million subtype E doses, and a vaccine based on pol required 4.8 million subtype G doses. For prophylactic vaccines targeting the most common HIV-1 subtype in each country, 1.9 billion doses of subtype A vaccine were estimated globally, followed by subtype C (1.1 billion) and subtype B (1.0 billion). A vaccine based on env required 1.2 billion subtype E doses, and a vaccine based on pol required 0.3 billion subtype G doses. If subtype-specific HIV-1 vaccines are also directed against less common subtypes in each country, vaccines targeting subtypes D, F, H, and K are also needed and would require up to five times more vaccine doses in total. We conclude that to provide global coverage, subtype-specific HIV-1 vaccines need to be directed against subtypes A, B, and C. Vaccines targeting env also need to include subtype E and those targeting pol need to include subtype G. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Frontiers Media | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | * |
dc.subject | CRF | es_ES |
dc.subject | HIV | es_ES |
dc.subject | URF | es_ES |
dc.subject | Recombinant | es_ES |
dc.subject | Subtype | es_ES |
dc.subject | Vaccine | es_ES |
dc.title | Global and Regional Estimates for Subtype-Specific Therapeutic and Prophylactic HIV-1 Vaccines: A Modeling Study | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución-NoComercial-CompartirIgual 4.0 Internacional | * |
dc.identifier.pubmedID | 34335516 | es_ES |
dc.format.volume | 12 | es_ES |
dc.format.page | 690647 | es_ES |
dc.identifier.doi | 10.3389/fmicb.2021.690647 | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.relation.publisherversion | https://doi.org/10.3389/fmicb.2021.690647 | es_ES |
dc.identifier.journal | Frontiers in microbiology | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |